Cytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a...

Area of Science:

• Hematology
• Infectious Diseases
• Transplantation Medicine

Background:

• Cytomegalovirus (CMV) infection is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), affecting 30-50% of patients.
• Identifying risk factors for CMV infection is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the risk factors associated with the development of CMV infection in patients undergoing allo-HSCT.

Main Methods:

• A retrospective analysis of 196 patients with hematological malignancies who underwent allo-HSCT.
• Propensity score matching (1:1) for gender and age was used to compare CMV-infected patients with a control group.

Main Results:

• Univariate analysis indicated a higher incidence of CMV infection in acute lymphoblastic leukemia (ALL) patients compared to acute myeloid leukemia (AML) patients (p = .012).
• Elevated blood cyclosporine levels and Graft-versus-Host Disease (GvHD) were significantly correlated with CMV infection (p = .006 and p < .001, respectively).
• Multivariate analysis identified defibrotide prophylaxis for VOD prophylaxis as a risk factor for CMV positivity.

Conclusions:

• Defibrotide prophylaxis was the sole identified risk factor for CMV positivity in multivariate analysis.
• While defibrotide is being studied for GvHD prophylaxis, its definitive role as a CMV risk factor requires further investigation.
• Focusing on prophylactic treatments during transplantation is essential for identifying CMV risk factors.